Tumor molecular heterogeneity is a major reason that patients with cancer with a similar tumor histology and clinical stage can have a very different clinical outcome and response to treatment with chemotherapy and biologics (e.g., antibodies against the epidermal growth factor receptors and insulin growth factor receptor). The gene discussed is EGFR; the disease is neoplasm.